Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agnico Eagle Mines Ltd (AEM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Agnico Eagle Mines LtdTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Agnico Eagle Mines Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Agnico Eagle Mines Ltd trades at $185.77 (market cap $92.01B), while State Street SPDR S&P Biotech ETF trades at $158.89. The key difference: Agnico Eagle Mines Ltd pays a 0.99% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Agnico Eagle Mines Ltd nearer its low. Which is the better fit depends on your goals.

AEMXBI
Market Cap
$92.01B
Sector
Basic MaterialsBroad Market / Factor
52-Week High
$252.19$164.28
52-Week Low
$130.23$86.92
Enterprise Value
$88.85B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agnico Eagle Mines Ltd

Agnico Eagle Mines (AEM) trades at $180.48, up 0.93% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust fundamentals with a P/E of 15.56, net income margin of 40.44%, and record free cash flow of $6.82B in 2025. Recent news highlights operational strength amid gold price gains, though cost pressures are noted.

Outlook remains positive with a $219.63 price target and 67.7% buy ratings, supported by organic growth plans. Risks include rising production costs and gold price volatility. The stock offers upside potential but faces margin compression headwinds in 2026.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Agnico Eagle Mines Ltd

Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.

Read more on AEM

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI